Author

Adel Mandl

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID 0000-0002-2852-7280Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Brian P. HanrattyiD· 1 shared D. Marc Rosen· 1 shared Hugh Young RienhoffiD· 1 shared Ilsa M. ColemaniD· 1 shared Isaacs Jt· 1 shared Jan Hendrik BeumeriD· 1 shared Laura A. SenaiD· 1 shared Lizamma Antony· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Brian P. HanrattyORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJan 17, 2024

Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype

Sumer Jasmine, Rajendra Kumar, Sunghyun Kim…·William Nathaniel Brennen

This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.

7 citations

humanbulk RNA-seq

𝕏 PostBluesky